Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Lonely product seeks patients to recover costs of development

This article was originally published in Scrip

Executive Summary

One of the consequences of the sequencing of the human genome in 2000 is the large number of biotechnology companies developing new drugs. Theoretically, at some point the number of companies will exceed the number of possible indications in human disease. But before we get to that stage, there are already quite a few of drugs that have been approved for such small indications that their costs of development can never be recovered.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026567

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel